GemPharmatech's NCG portfolio is one of the most comprehensive sets of immunodeficient mouse models, making it ideal for cancer immunotherapy research using immunological reconstitution via transplantation of human peripheral blood mononuclear cells (PBMC) and human hematopoietic stem cells (CD34+HSC). Humanized immune system mouse models, such as huPBMC-NCG and huHSC-NCG models, are mice injected with human cells such as human hematopoietic cells, lymphocytes, or tissues. Humanized immune system mice combined with CDX or PDX can be used to study tumor growth and evaluate anti-tumor therapies. NCG and all strains of next-generation NCG mice are developed using CRISPR-Cas9 technology on pure inbred NOD/ShiLtJGpt background, by knocking out the Prkdc (Protein kinase, DNA activated, catalytic polypeptide) and Il2rg (interleukin-2 receptor subunit gamma) genes.
